An improved retroviral vector encoding the herpes simplex virus thymidine kinase gene increases antitumor efficacy in vivo.
Brain tumors have been treated clinically by intratumoral injection of cells that produce retroviral vectors encoding the herpes simplex virus thymidine kinase (HSV-TK) gene followed by systemic administration of the antiviral drug ganciclovir. In vitro and in vivo comparisons of two different HSV-TK vector producer clones, which were made using standard transfection and transinfection techniques, were conducted. The two clones, PA317/G1TkSvNa.53 (TK.53) and PA317/G1Tk1SvNa.7 (TK1.7), both used in clinical trials, differ with respect to sequences 3' to the HSV-TK stop codon. The retroviral construct used to generate the TK.53 vector producer cell clone contains an open reading frame encoding a portion of the herpes simplex virus glycoprotein H (gH), a potential polyadenylation site and a putative splice site in this region. These sequences were removed from the retroviral construct used to create the TK1.7 vector producer cell clone. Supernatants obtained from TK1.7 vector producer cells had 100- to 1000-fold higher titers (G418 or HAT) than did corresponding supernatants from TK.53 vector producer cells. A murine subcutaneous tumor model was used to assess transduction efficiency and antitumor activity of each vector producer cell clone. In vivo tumor cell transduction was 13- to 18-fold more efficient with TK1.7 cells as compared with TK.53 cells at equivalent doses. Complete tumor ablation was achieved using a 10-fold lower dose of TK1.7 cells as compared with TK.53 cells. These results suggest that TK1.7 cells combined with ganciclovir may provide a more potent antitumor response in humans.
Lyons
R M
RM
Genetic Therapy, Inc, Gaithersburg, Maryland 20878, USA.
Forry-Schaudies
S
S
Otto
E
E
Wey
C
C
Patil-Koota
V
V
Kaloss
M
M
McGarrity
G J
GJ
Chiang
Y L
YL
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D015139:Blotting, Southern; D002999:Clone Cells; D003001:Cloning, Molecular; D017931:DNA Primers; D004273:DNA, Neoplasm / Q000032:analysis; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy / Q000628:therapy*; D015774:Ganciclovir / Q000627:therapeutic use; D005814:Genes, Viral; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D011533:Proviruses; D012190:Retroviridae; D018139:Simplexvirus / Q000201:enzymology*; D013937:Thymidine Kinase / Q000096:biosynthesis / Q000235:genetics / Q000627:therapeutic use*; D014162:Transfection / Q000379:methods; D014407:Tumor Cells, Cultured; D014764:Viral Proteins / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D017931:DNA Primers; D004273:DNA, Neoplasm; D004279:DNA, Viral; D014764:Viral Proteins; D013937:Thymidine Kinase; D015774:Ganciclovir